Chris Dvergsten

Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study

M. Hale, Chris Dvergsten, Joseph Gimbel · Journal of Pain · 2004 · 154 citations

Pain Therapy, Pain Research, Health Sciences +7

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia

David P. Walling, Stephen R. Marder, John M. Kane et al. · Schizophrenia Bulletin · 2015 · 96 citations · Full text

Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study

Nashat Gabrail, Chris Dvergsten, Harry Ahdieh · Current Medical Research and Opinion · 2004 · 79 citations

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes

Klara R. Klein, Jennifer L. R. Freeman, Imogene Dunn et al. · Diabetes Care · 2021 · 39 citations · Full text

TRIPHENYL PHOSPHITE NEUROPATHY DIFFERS FROM ORGANOPHOSPHORUS‐INDUCED DELAYED NEUROPATHY IN RATS

Bellina Veronesi, Chris Dvergsten · Neuropathology and Applied Neurobiology · 1987 · 26 citations